Interesting study – A meta-analysis of nonrelapse mortality after CAR T cell therapy

Vivek Subbiah shared on X:

“Interesting study published in NatureMedicine:

• A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
• 7,604 patients across 18 clinical trials+ 28 real-world studies.
• Of 574 reported nonrelapse deaths, over half were attributed to infections (50.9%), other malignancies (7.8%) & cardiovascular/respiratory events (7.3%).
• Very important to monitor for infectious complications after CAR T cell therapy “

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

Authors: David M. Cordas dos Santos, Tobias Tix, Roni Shouval, Anat Gafter-Gvili, Jean-Baptiste Alberge, Edward R. Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt-Baildon, Irene M. Ghobrial, Marion Subklewe, Miguel-Angel Perales and Kai Rejeski.

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.